DZ3366A1 - Derives de 4,5-dihydro-thiazol-2-ylamine et leur utilisation comme inhibiteurs de no synthase - Google Patents

Derives de 4,5-dihydro-thiazol-2-ylamine et leur utilisation comme inhibiteurs de no synthase

Info

Publication number
DZ3366A1
DZ3366A1 DZ013366A DZ013366A DZ3366A1 DZ 3366 A1 DZ3366 A1 DZ 3366A1 DZ 013366 A DZ013366 A DZ 013366A DZ 013366 A DZ013366 A DZ 013366A DZ 3366 A1 DZ3366 A1 DZ 3366A1
Authority
DZ
Algeria
Prior art keywords
thiazol
dihydro
synthase inhibitors
ylamine derivatives
ylamine
Prior art date
Application number
DZ013366A
Other languages
English (en)
French (fr)
Inventor
Jean-Christophe Carry
Dominique Damour
Claude Guyon
Serge Mignani
Eric Bacque
Antony Bigot
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DZ3366A1 publication Critical patent/DZ3366A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
DZ013366A 2000-06-09 2001-06-07 Derives de 4,5-dihydro-thiazol-2-ylamine et leur utilisation comme inhibiteurs de no synthase DZ3366A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0007396A FR2810036B1 (fr) 2000-06-09 2000-06-09 Derives de 4,5-dihydro-1,3-thiazol-2-ylamine, leur preparation et les compositions phamarceutiques les contenant
PCT/FR2001/001759 WO2001093867A1 (fr) 2000-06-09 2001-06-07 Derives de 4,5-dihydro-thiazol-2-ylamine et leur utilisation comme inhibiteurs de no synthase

Publications (1)

Publication Number Publication Date
DZ3366A1 true DZ3366A1 (fr) 2001-12-13

Family

ID=8851133

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013366A DZ3366A1 (fr) 2000-06-09 2001-06-07 Derives de 4,5-dihydro-thiazol-2-ylamine et leur utilisation comme inhibiteurs de no synthase

Country Status (27)

Country Link
EP (1) EP1299103B1 (ko)
JP (1) JP4171297B2 (ko)
KR (1) KR20030017990A (ko)
CN (1) CN1441673A (ko)
AP (1) AP2002002707A0 (ko)
AT (1) ATE305298T1 (ko)
AU (2) AU2001266123B2 (ko)
BR (1) BR0111543A (ko)
CA (1) CA2411572C (ko)
DE (1) DE60113686T2 (ko)
DK (1) DK1299103T3 (ko)
DZ (1) DZ3366A1 (ko)
EA (1) EA200300009A1 (ko)
EC (1) ECSP024374A (ko)
ES (1) ES2246327T3 (ko)
FR (1) FR2810036B1 (ko)
HR (1) HRP20020971A2 (ko)
HU (1) HUP0300996A3 (ko)
IL (1) IL153327A0 (ko)
MA (1) MA25815A1 (ko)
MX (1) MXPA02012072A (ko)
NO (1) NO20025885L (ko)
NZ (1) NZ522967A (ko)
OA (1) OA12285A (ko)
PL (1) PL360282A1 (ko)
WO (1) WO2001093867A1 (ko)
ZA (1) ZA200209770B (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088935B2 (en) 2003-12-23 2012-01-03 Ironwood Pharmaceuticals, Inc. Compounds and methods for the treatment of asthma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08503940A (ja) * 1992-11-27 1996-04-30 ザ ウエルカム ファウンデーション リミテッド 酵素阻害薬
KR100342275B1 (ko) * 1993-10-21 2002-12-05 지.디. 썰 엘엘씨 산화질소신타제저해제로서유용한아미디노유도체
WO1996014842A1 (en) * 1994-11-15 1996-05-23 Merck & Co., Inc. Substituted heterocycles as inhibitors of nitric oxide synthase

Also Published As

Publication number Publication date
EA200300009A1 (ru) 2003-04-24
CN1441673A (zh) 2003-09-10
AP2002002707A0 (en) 2002-12-31
ES2246327T3 (es) 2006-02-16
ZA200209770B (en) 2004-03-02
OA12285A (en) 2006-05-12
JP4171297B2 (ja) 2008-10-22
NO20025885D0 (no) 2002-12-06
AU2001266123B2 (en) 2007-01-25
WO2001093867A1 (fr) 2001-12-13
MXPA02012072A (es) 2004-08-19
MA25815A1 (fr) 2003-07-01
HRP20020971A2 (en) 2005-02-28
FR2810036B1 (fr) 2004-04-23
DE60113686T2 (de) 2006-07-13
ECSP024374A (es) 2003-02-06
NZ522967A (en) 2005-07-29
DE60113686D1 (de) 2006-02-09
CA2411572A1 (fr) 2001-12-13
HUP0300996A3 (en) 2006-02-28
BR0111543A (pt) 2003-07-01
CA2411572C (fr) 2009-11-10
DK1299103T3 (da) 2006-01-23
EP1299103B1 (fr) 2005-09-28
FR2810036A1 (fr) 2001-12-14
EP1299103A1 (fr) 2003-04-09
JP2003535135A (ja) 2003-11-25
HUP0300996A2 (hu) 2003-08-28
PL360282A1 (en) 2004-09-06
AU6612301A (en) 2001-12-17
ATE305298T1 (de) 2005-10-15
NO20025885L (no) 2003-01-29
KR20030017990A (ko) 2003-03-04
IL153327A0 (en) 2003-07-06

Similar Documents

Publication Publication Date Title
MA27001A1 (fr) Derives spirotricycliques nouveaux et leur utilisation comme inhibiteurs de phospho-diesterase-7
DZ3186A1 (fr) Ptéridinones utilisées comme inhibiteurs de kinase.
PT1226136E (pt) Inibidores da tirosina quinase
MA26771A1 (fr) Benzoheterocycles et leur utilisation comme inhibiteurs de mek.
MXPA03004794A (es) Derivados de acido mandelico y su uso como inhibidores de trombina.
CY2007002I1 (el) Ω-καρβοξυαρυλυποκατεστημενες διφαινυλουριες σαν αναστολεις της raf κινασης
AR028576A1 (es) Derivados de b-carbolina utiles como inhibidores de fosfodiesterasa
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
SI1686119T1 (sl) Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
DZ3439A1 (fr) Derives de 2-aminocarbonyl-9h-purine
MA26976A1 (fr) Derives du tetrahydropyridine, leur preparation et leur utilisation comme inhibiteur de proliferation de cellules
DZ3415A1 (fr) Guanidinobenzamides comme mc4-r agonistes.
PT1194404E (pt) Inibidores de aspartil-protease
FR2806720B1 (fr) Derives de 2,2,6,6-diethyl-dimethyl-1-alcoxypiperidines et 1-oxydes correspondants
MXPA03003314A (es) Compuestos de c-nitrosoanilina y sus mezclas como inhibidores de polimerizacion.
PT1171440E (pt) 3-ciano-¬1,7|,¬1,5|, e ¬1,8|-naftiridinas substituidas inibidoras de tirosina quinases
FR2810318B1 (fr) Derives de diamano-phenothiazine
IL148275A0 (en) Substituted 3-phenyl-5-alkoxy-1, 3, 4-oxdiazol-2-ones- and their use as lipase inhibitors
AR028607A1 (es) Derivados de 1,4-diazepan-2,5-diona
MA25814A1 (fr) Derives de 2-aminothiazoline et leur utilisation comme inhibiteurs de no-synthase.
DZ3366A1 (fr) Derives de 4,5-dihydro-thiazol-2-ylamine et leur utilisation comme inhibiteurs de no synthase
AU2001293869A1 (en) Butenolide and pentenolide derivatives as kinase inhibitors
EE04494B1 (et) 1-oksa-, asa- ja tianaftaleen-2-oon biseetrid fosfolambaani inhibiitoritena
ATE264308T1 (de) Aminoalkyl-3,4-dihydrochinolin-derivate als no synthase inhibitoren
ZA200206528B (en) Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors.